For the patient with metastatic breast cancer who is already cycling through standard chemotherapy, or the insomnia patient who has worked through trazodone and cognitive behavioral therapy without relief, the question of whether a cannabis-derived molecule could help is not academic. It is a question their oncologist or sleep specialist is rarely equipped to answer, because the underlying clinical evidence has been thin, fragmented, and largely uncontrolled. Cannasoul R&D Ltd., a Herzliya-based research company spun out of the Technion, is trying to change what that conversation sounds like.
In early November, InterCure Ltd., one of the largest licensed cannabis operators in Israel, signed a definitive agreement to take an initial 28% stake in Cannasoul with an option to move to 51%, paired with a research and commercialization collaboration [GlobeNewswire, Nov 2025]. The deal also installs Cannasoul founder Prof. Dedi Meiri as chair of a new InterCure Scientific Advisory Board [Cannabis Business Times, Nov 2025]. Financial terms were not disclosed.
The bet
Cannasoul's wedge is not a single molecule or a single indication. It is the lab itself. CannaSoul Analytics is GCLP approved, accredited under ISO/IEC 17025, and operates under the supervision of the Israel Health Ministry's Cannabis Unit, known as Yakar [Neoteryx]. That accreditation stack matters, because it is the floor regulators expect before any data generated in a facility can be folded into a regulatory submission to the FDA, EMA, or Israel's own Ministry of Health. A subsidiary, MyPlant Bio, has built a library of cell-based disease models used to screen plant extracts for biological activity [Health Europa, Jul 2020] [Labguru]. The pitch to a partner like InterCure is straightforward: bring the plant material and the commercial channel, and Cannasoul will run the science that turns a cultivar into something a clinician might one day prescribe.
The company's most visible work to date sits at the intersection of cannabis chemistry and inflammation. In 2020, Cannasoul partnered with Israeli terpene firm Eybna to test NT-VRL, a proprietary terpene formulation, against the cytokine storm seen in severe viral infection [Markets Insider, Apr 2020]. Initial in vitro results suggested that the addition of CBD to the NT-VRL formulation produced the highest inhibition of inflammatory cytokines tested in the model [Health Europa, Jul 2020]. Those findings were preclinical, conducted in cell-based assays rather than in patients, and have not advanced through a published controlled clinical trial that this reporter could verify. They are best read as hypothesis-generating, not practice-changing.
Why the InterCure deal could matter
The standard of care across Cannasoul's stated indication areas looks very different from one disease to the next, but shares a common gap. In metastatic breast cancer, treatment is built around endocrine therapy, CDK4/6 inhibitors, HER2-targeted agents, and chemotherapy regimens, with cannabis playing only a palliative role for nausea and appetite under most oncology guidelines. In chronic insomnia, first-line care remains cognitive behavioral therapy for insomnia (CBT-I), with pharmacologic options including low-dose doxepin, dual orexin receptor antagonists, and the older z-drugs. Medical cannabis is used widely off-label by patients in both populations, but prescribers have very little randomized evidence to guide dose, cultivar, or cannabinoid ratio. That evidence vacuum is precisely the space Cannasoul is positioning to fill.
The InterCure tie-up gives that ambition a commercial spine. InterCure operates at scale in Israel and has been building exposure to the U.S. market through ISHI and a relationship with The Flowery [StockTitan, Nov 2025]. If the U.S. Drug Enforcement Administration moves cannabis to Schedule III, as has been under public discussion, the regulatory pathway for cannabis-derived investigational drugs becomes meaningfully less constrained for U.S.-based trial sponsors. A research partner with accredited analytics, an existing cell-model library, and an academic principal investigator embedded at the Technion is a more useful asset in that scenario than in the current one.
Team and backers
Prof. Dedi Meiri, who serves as Chairman and CSO of Cannasoul [Markets Insider, Apr 2020], runs the Laboratory of Cancer Biology and Cannabinoid Research at the Technion and is among the more frequently cited cannabis researchers globally [GlobeNewswire, Nov 2025]. The company was co-founded with the Technion Research & Development Foundation, the institute's commercialization arm [StreetInsider]. Prior outside investors include TAO Synergies and Synaptogenix, the latter having previously taken a significant stake in CannaSoul Analytics [StreetInsider]. The 2025 round led by InterCure is labeled as seed in available databases, with the amount undisclosed [GlobeNewswire, Nov 2025] [Crunchbase].
| Event | Date | Lead / Partner | Disclosed terms |
|---|---|---|---|
| Eybna NT-VRL collaboration | Apr 2020 | Eybna | Preclinical research deal [Markets Insider, Apr 2020] |
| Synaptogenix stake | Prior | Synaptogenix | Significant stake, terms undisclosed [StreetInsider] |
| Venture round | Prior | TAO Synergies | Amount undisclosed [Crunchbase] |
| Strategic investment | Nov 2025 | InterCure | Initial 28%, option to 51% [GlobeNewswire, Nov 2025] |
What bears say, what bulls answer
The most credible concern is concentration. With InterCure able to move to a 51% controlling position [Cannabis Business Times, Nov 2025], Cannasoul's research agenda risks being shaped predominantly by one strategic partner's commercial roadmap, which could narrow the company's scientific aperture and complicate future partnerships with rival operators or pharmaceutical sponsors. The bull answer is in the structure of the deal itself: InterCure is paying for access to a research engine that already holds GCLP and ISO/IEC 17025 accreditation under Yakar supervision [Neoteryx], assets that take years to build, and is publicly committing to a collaboration framework rather than an outright acquisition. For Meiri, who retains his Technion appointment and now chairs InterCure's scientific advisory board [GlobeNewswire, Nov 2025], the arrangement preserves academic standing while routing commercial cash into the lab.
What to watch
The next twelve months will turn on whether Cannasoul and InterCure can convert the partnership announcement into a registered clinical program, ideally a Phase I or Phase II trial in an indication where the existing standard of care leaves obvious room: chemotherapy-induced nausea, refractory insomnia, or an inflammatory condition that builds on the NT-VRL preclinical work. Watch for an IND filing, an EMA scientific advice meeting, or a peer-reviewed publication out of the Meiri lab that moves the cytokine modulation work from cell models into animal or human data. Watch, too, for whether InterCure exercises its option to move from 28% to 51% [GlobeNewswire, Nov 2025], which would signal that early collaboration milestones are being met. Until then, Cannasoul's most important product remains the same one it has been building since 2018: a credentialed laboratory that can tell clinicians, with evidence rather than enthusiasm, what cannabis can and cannot do for their patients.